CAMBRIDGE, Mass.--(BUSINESS WIRE)--Passkey Therapeutics, the pioneer of Synergistic Multifunctional Therapeutics (SMThs), announced today that it has emerged from stealth with $20 million in seed funding led by Breakout Ventures along with founding investors Innovation Endeavors and Bison Ventures. Additional participants include Wireframe Ventures, Alexandria Venture Investments, and GRIDS Capital.

马萨诸塞州剑桥市。-（商业新闻短讯）--Passkey Therapeutics是协同多功能疗法（SMThs）的先驱，今天宣布，它已经从隐形中崛起，拥有2000万美元的种子资金，由突破性风险投资公司（Breakout Ventures）以及创始投资者创新努力和野牛风险投资公司（Bison Ventures）牵头。其他参与者包括Wireframe Ventures、Alexandria Venture Investments和GRIDS Capital。

The funding will support Passkey’s development of SMThs (pronounced “smiths”) — a new class of single-drug therapies designed to modulate rare combinations of proteins that work together — and Locksmith, the company’s proprietary computational and experimental platform for SMTh discovery..

这笔资金将支持Passkey开发SMTh（发音为“smiths”）——一种旨在调节共同作用的罕见蛋白质组合的新型单药疗法——以及该公司专有的SMTh发现计算和实验平台Locksmith。。

“Our platform represents a paradigm shift in drug discovery,” said Bruce Beutel, CEO of Passkey. “While conventional drug development has largely centered around single-protein targets, many diseases, including the most common ones, have complex underlying biology. Addressing these complex diseases demands a different approach – one that embraces and leverages that biological complexity.

Passkey首席执行官布鲁斯·贝特尔（BruceBeutel）表示：“我们的平台代表了药物发现的范式转变。”。“虽然传统的药物开发主要集中在单一蛋白质靶标上，但许多疾病，包括最常见的疾病，都有复杂的潜在生物学。解决这些复杂疾病需要一种不同的方法-一种拥抱和利用这种生物学复杂性的方法。

By identifying rare combinations of proteins that work together, we can open the door to a completely new target landscape and create a new class of therapies for patients with a wide variety of conditions..

通过鉴定共同作用的罕见蛋白质组合，我们可以为全新的目标领域打开大门，并为患有各种疾病的患者创造一类新的治疗方法。。

'With Locksmith, we have the speed and precision to achieve this, positioning Passkey at the forefront of developing multifunctional medicines that modulate multiple proteins simultaneously.”

“有了锁匠，我们有速度和精度来实现这一目标，将Passkey定位在开发同时调节多种蛋白质的多功能药物的前沿。”

Dana Watt, Ph.D., a Partner with Breakout Ventures, commented: “Recent advances, such as bispecific antibodies, have made progress in targeting multiple proteins, but no one has had a broad ability to pinpoint the optimal combinations for simultaneous treatment — until now. We are proud to support Passkey's approach to therapeutic discovery and design, which holds immense promise for tackling the complexities of multifactorial diseases with greater efficacy.”.

Breakout Ventures的合作伙伴Dana Watt博士评论道：“最近的进展，如双特异性抗体，在靶向多种蛋白质方面取得了进展，但到目前为止，还没有人有广泛的能力确定同时治疗的最佳组合。我们很骄傲地支持Passkey的治疗发现和设计方法，这对于以更大的疗效解决多因素疾病的复杂性具有巨大的希望。”。

Embracing Biological Complexity

拥抱生物复杂性

Passkey’s proprietary Locksmith platform uses advanced computational and experimental tools to analyze extensive human genetic datasets and identify previously undiscovered combinations of proteins — termed 'Multilogs' — that work in concert. The proteins in these groups often have limited therapeutic impact when targeted individually but reveal powerful potential when addressed together..

Passkey专有的锁匠平台使用先进的计算和实验工具来分析广泛的人类遗传数据集，并识别以前未发现的蛋白质组合，称为“多重对数”，它们协同工作。这些组中的蛋白质在单独靶向时通常具有有限的治疗效果，但在一起解决时显示出强大的潜力。。

Beutel added, “Passkey is engineering Synergistic Multifunctional Therapeutics precisely tailored to multiple distinct proteins. These therapies could take the form of small molecules or biologics, such as antibodies, depending on the biology of the particular disease. By advancing beyond single-protein targets with our innovative approach, we believe we can make a significant difference for patients.”.

。

Advancing Programs Across Multiple Therapeutic Areas

跨多个治疗领域推进项目

Passkey’s approach offers a new way to address many conditions, including cancer, autoimmune and neurodegenerative disorders, and metabolic diseases. The company is progressing its internal pipeline with plans to internally develop SMThs in two distinct therapeutic areas through clinical trials, while also exploring potential partnerships in additional areas..

。该公司正在推进其内部渠道，计划通过临床试验在两个不同的治疗领域内部开发SMT，同时还探索其他领域的潜在合作伙伴关系。。

“Passkey is making a major contribution to our ability to leverage the rapidly increasing availability of human genetic data to finally be able to address some of the most challenging diseases — those that are too complex to solve with a single-target approach,” said Joel Dudley, Ph.D., a Partner with Innovation Endeavors.

创新努力的合作伙伴乔尔·达德利博士说：“Passkey正在为我们利用人类遗传数据快速增长的可用性做出重大贡献，最终能够解决一些最具挑战性的疾病-那些太复杂而无法用单一目标方法解决的疾病。”。

“With a focused early pipeline and a clear strategic vision, we believe Passkey is well-positioned to make significant strides in using the underlying complexity of disease to our advantage, and we are excited to support their efforts.”.

。

Veteran Team Steers Company Mission

资深团队引领公司使命

Passkey was founded by a team of seasoned experts, each bringing complementary strengths to advance the company's mission. Bruce Beutel, Ph.D., has decades of experience in pharmaceutical and biotech R&D, business development, and company-building. Soumya Ray, Ph.D., and Will Chen, Ph.D., leverage their deep expertise in computational biology, chemistry, and genetics to co-lead the development of the Locksmith platform..

Passkey是由一支经验丰富的专家团队创立的，每个人都有互补的优势来推进公司的使命。Bruce Beutel博士在制药和生物技术研发、业务开发和公司建设方面拥有数十年的经验。。。

About Passkey Therapeutics

关于Passkey Therapeutics

Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs), designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions..

Passkey Therapeutics开创了一类新的药物，即协同多功能疗法（SMThs），旨在通过靶向共同作用的罕见蛋白质组合来解决复杂疾病。该公司利用其专有的锁匠平台，在多个治疗领域推进项目，为患有常见难治性疾病的患者创造新的选择。。

For more information, visit passkeytx.com and follow us on LinkedIn.

有关更多信息，请访问passkeytx.com并在LinkedIn上关注我们。